Report Overview

The Indian Interstitial Cystitis Drugs Market size stood at around USD XX Billion in 2019 and is projected to reach USD XX million by 2028, exhibiting a CAGR of XX% during the forecast period.

Interstitialcystitis (IC),also known as painful bladder syndrome, is a chronic bladder issue often associated with bladder pressure and pain, with occasional pain in either the lower abdomen, pelvic, or lower back. The patient could experience pain raging from mild to severe. The pelvic nerve signal to the brain gets mixed up in an individual suffering from interstitial cystitis. Consequently, an urgency to urinate, often in a small volume, is observed. On an average, a person urinates seven times a day; however, in severe cases ofIC,urination may occur around 40-60 times a day. IC is not an infection, but is often mistaken to be a bladder infection.Factorscontributing to interstitial cystitis are: a defect of the epithelium layer of the bladder, leaking epithelium allows toxic agents in urine to irritate the bladder wall. Other anticipated, but not clear, contributing factors include heredity, an autoimmune reaction, infection or allergy.



Market Drivers

The growth of interstitial cystitis market enhanced by the growing cases of interstitial cystitis as well as bladder trauma or overstretching and rise in research and development activities, advances in the technology and adoption of sedentary life-style are some of the impacting factors for the demand of interstitial cystitis drugs. Nevertheless, high treatment cost coupled with lack of skilled professionals are the factors that hinder the growth of this market.